A RANDOMIZED PHASE II TRIAL COMPARING TWO DIFFERENT SEQUENCE COMBINATIONS OF AUTOLOGOUS VACCINE AND HUMAN RECOMBINANT INTERFERON γ AND HUMAN RECOMBINANT INTERFERON α2B THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: CLINICAL OUTCOME AND ANALYSIS OF IMMUNOLOGICAL PARAMETERS

Abstract

AV with IFNgamma and IFNalpha therapy might induce a MHC class-mediated cytotoxic T lymphocyte (CTL) response. We suggest that adequate therapy might direct T cell response toward a Th1 type response. We hypothesize a state of improved immune readiness in patients who might eventually respond to immunotherapy.